logo

Search

Login | Create Account

cardiology


Categories

Arrhythmia End-of-life care Heart failure Interventional cardiology Ischaemic heart disease Medicines Medicopolitical Podcasts Public health Research Risk factors Vascular disease

Other

Conferences Praluent hub

Specialties


Cardiology Dermatology Endocrinology Gastroenterology Haematology Neurology Oncology Respiratory Rheumatology

General


Contact Us About Us Website Disclaimer Privacy Policy Terms & Conditions

©2022 the limbic

logo

CSANZ 2020

Thursday 1st - Thursday 1st January 1970

Ischaemic heart disease

Doubts over troponin rapid rule out tests for MI after RAPID-TNT results revealed

Questions are being raised about the benefit of high sensitivity cardiac troponin (hs-cTnT) as part of a rapid 0/1-hour MI rule out protocol for patients with suspected ACS  following negative results from 12 month follow up data of the...

Questions are being raised about the benefit of high sensitivity cardiac troponin (hs-cTnT) as part of a rapid 0/1-hour...


Will ISCHEMIA study findings be translated into practice for patients with stable CAD?

The landmark findings of the ISCHEMIA trial favouring conservative therapy for stable coronary artery disease (CAD) are at risk of being overlooked because of the COVID-19 pandemic, according to a panel discussion at CSANZ 2020. The study results, first released...

The landmark findings of the ISCHEMIA trial favouring conservative therapy for stable coronary artery disease (CAD) are at risk of...


Heart failure

3 novel therapies for heart failure – Prof John Teerlink

With SGLT2 inhibitors now joining the mainstream of therapies for heart failure, it’s time to look at other novel approaches such as intravenous iron, vericiguat and omecamtiv mercarbil, according to an international expert. Speaking at CSANZ 2020 virtual meeting, Professor John...

With SGLT2 inhibitors now joining the mainstream of therapies for heart failure, it’s time to look at other novel approaches...


Cancel
Cancel